New analogs of the compstatin family of clinical complement inhibitors with low picomolar target affinity
Authors:
- Stephanie VogtSVStephanie Vogt
- Alexander J. LanderALAlexander J. Lander
- Ekaterina UmnyakovaEUEkaterina Umnyakova
- Roman AschwandenRARoman Aschwanden
- Sarah E. HughesSHSarah E. Hughes
- Oliver SchwardtOSOliver Schwardt
- Markus A. LillMLMarkus A. Lill
- Martin SmieškoMartin Smieško
- John D. LambrisJLJohn D. Lambris
- Christina LamersCLChristina Lamers
- Daniel RicklinDRDaniel Ricklin
Preprint
- 4 November 2025
- preprint
- Published by American Chemical Society (ACS) in ChemRxiv
Abstract
Macrocyclic peptides of the compstatin family have emerged as therapeutic complement system modulators. Alongside an approved PEGylated derivative, sequence-optimized compstatin analogs with enhanced PK/PD properties have shown clinical promise. By extending the structure-activity relationship of compstatin, we characterized a highly beneficial V3I modification that enhances compstatin’s target affinity up to 30-fold and show that the additional gamma-methyl group addresses a specific target pocket. Novel analog Cp01-V3I represents the most potent analog comprised entirely of canonical amino acids (KD = 20 nM), opening a path toward recombinant applications. Meanwhile, the V3I modification can be transferred to late-generation analogs to obtain a low-picomolar-affinity derivative (KD = 0.08 nM), termed Cp60, with potent complement inhibition in vitro. Lastly, we demonstrate that Cp60’s ultra-long target residence enables new applications as a diagnostic tool for the detection of complement opsonins on biosurfaces. Collectively, this work highlights the importance of vigorous optimization of de novo peptide inhibitors to improve PK/PD properties and enable novel applications.Keywords
All Related Versions
- Version 1, 2025-11-04, ChemRxiv
- Published version: Journal of Medicinal Chemistry, 69 (9), 11592.
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (205321_204607)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A_176104)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_219969)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (TMPFP3_224990)
This publication has 34 references indexed in Scilit:
- Complement‐targeted therapeutics: Are we there yet, or just getting started?European Journal of Immunology, 2024
- Complement‐targeted therapeutics: An emerging field enabled by academic drug discoveryAmerican Journal of Hematology, 2023
- Pegcetacoplan: First ApprovalDrugs, 2021
- The first case of COVID-19 treated with the complement C3 inhibitor AMY-101Clinical Immunology, 2020
- Clinical Pharmacokinetics and Pharmacodynamics of AlbiglutideClinical Pharmacokinetics, 2017
- Evaluation of Complement Function by ELISA2013
- New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic propertiesImmunobiology, 2013
- Paths reunited: Initiation of the classical and lectin pathways of complement activationImmunobiology, 2010
- Integrated Modeling Program, Applied Chemical Theory (IMPACT)Journal of Computational Chemistry, 2005
- Solution structure of Compstatin, a potent complement inhibitorProtein Science, 1998